The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
|Articles|July 16, 2013
ASHP to Testify at House Hearing on Compounding
Advertisement
PRESS RELEASE
July 16, 2013--ASHP is scheduled to testify today at a congressional hearing on reforming the regulatory framework of pharmacy compounding.
Kasey K. Thompson, Pharm.D., M.S., ASHP vice president of policy, planning, and communications, will represent the Society at the hearing called by the
ASHP members are encouraged to
The hearing will be broadcast at 3:00 p.m. on the Committee's
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
2
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
3
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5